Browsing Tag
oncology reimbursement
1 post
I-SPY 2 data puts Natera’s Signatera at the center of early breast cancer risk debates
Natera’s I-SPY 2 data suggests ctDNA may finally align early breast cancer risk with treatment intensity. Read why this matters for payers and markets.